Sage Therapeutics Inc (NASDAQ: SAGE) stock jumped 3.12% on Friday to $19.16 against a previous-day closing price of $18.58. With 0.94 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $19.42 whereas the lowest price it dropped to was $18.66. The 52-week range on SAGE shows that it touched its highest point at $59.99 and its lowest point at $16.51 during that stretch. It currently has a 1-year price target of $25.50. Beta for the stock currently stands at 1.10.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SAGE was up-trending over the past week, with a rise of 12.05%, but this was up by 5.04% over a month. Three-month performance dropped to -2.39% while six-month performance fell -63.87%. The stock lost -45.44% in the past year, while it has lost -49.76% so far this year. A look at the trailing 12-month EPS for SAGE yields -10.98 with Next year EPS estimates of -6.09. For the next quarter, that number is -1.07. This implies an EPS growth rate of -4.12% for this year and 34.84% for next year. EPS is expected to grow by 41.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -4.86%.
Float and Shares Shorts:
At present, 59.51 million SAGE shares are outstanding with a float of 51.49 million shares on hand for trading. On Oct 30, 2023, short shares totaled 8.61 million, which was 14.35% higher than short shares on Sep 28, 2023. In addition to Mr. Barry E. Greene as the firm’s President, CEO & Director, Ms. Kimi E. Iguchi CPA serves as its CFO & Treasurer.
Institutional Ownership:
Other institutions hold 56.39% of SAGE, in contrast to 41.74% held by mutual funds. Shares owned by individuals account for 4.49%. As the largest shareholder in SAGE with 12.85% of the stake, Fidelity Management & Research Co holds 7,695,906 shares worth 7,695,906. A second-largest stockholder of SAGE, Wellington Management Co. LLP, holds 6,572,260 shares, controlling over 10.98% of the firm’s shares. RTW Investments LP is the third largest shareholder in SAGE, holding 5,149,482 shares or 8.60% stake. With a 5.98% stake in SAGE, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 3,582,565 shares are owned by the mutual fund manager. The BB Biotech AG, which owns about 5.14% of SAGE stock, is the second-largest Mutual Fund holder. It holds 3,080,000 shares valued at 57.69 million. Vanguard Health Care Fund holds 5.03% of the stake in SAGE, owning 3,010,218 shares worth 56.38 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SAGE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SAGE analysts setting a high price target of $79.00 and a low target of $18.00, the average target price over the next 12 months is $25.50. Based on these targets, SAGE could surge 312.32% to reach the target high and fall by -6.05% to reach the target low. Reaching the average price target will result in a growth of 33.09% from current levels.
Summary of Insider Activity:
Insiders traded SAGE stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 15 while that of sell transactions has risen to 7 over the past year. The total number of shares bought during that period was 45,474 while 18,210 shares were sold.
